文献速递肺栓塞与肺血管病

内皮素受体拮抗剂联合磷酸二酯酶5抑制剂治疗肺动脉高压的网状Meta分析

[Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2022-01-01

结果显示波生坦联合西地那非在12-16周6分钟步行距离改善最显著,联合治疗安全性与单药无显著差异。

要点

  • 波生坦联合西地那非在改善6分钟步行距离方面排名最高(SUCRA 82.9%)。
  • 波生坦联合他达拉非在降低临床恶化率方面表现最优(OR=0.08)。
  • 联合治疗与单药治疗在不良事件和严重不良事件发生率上无显著差异。

核心结论

  • 内皮素受体拮抗剂与磷酸二酯酶5抑制剂联合治疗在短期改善运动功能方面表现较好,安全性上与单药治疗无明显差异。
  • 未来选择治疗方案时应根据患者个体化情况和需求进行选择。

研究设计与样本

  • 研究为网状Meta分析,检索PubMed、Cochrane Library、CNKI、万方和维普数据库截至2021年2月12日。
  • 主要结局为12-16周6分钟步行距离变化,次要结局包括病死率、临床恶化、WHO心功能分级改善、不良事件和严重不良事件。

主要发现

  • 与安慰剂相比,波生坦联合西地那非改善6分钟步行距离最大(WMD=53.93,95%CI:6.19-101.66)。
  • 提高WHO心功能分级方面,西地那非最优(OR=2.90,95%CI:1.04-8.08),其次为波生坦(OR=2.15,95%CI:1.15-4.04)。
  • 降低临床恶化率方面,波生坦联合他达拉非最优(OR=0.08,95%CI:0.01-0.49)。
  • 所有干预措施与安慰剂在不良事件和严重不良事件发生率上差异均无统计学意义。
  • 病死率方面,安立生坦优于安慰剂(OR=0.28,95%CI:0.11-0.74),其余差异无统计学意义。

关键数值与推荐

  • 6分钟步行距离改善的SUCRA排序:波生坦+西地那非(82.9%)>波生坦+他达拉非(78.4%)>安立生坦+他达拉非(77.1%)>波生坦(49.2%)>西地那非(48.5%)>安立生坦(40.3%)>马西腾坦(37.3%)>他达拉非(33.0%)>安慰剂(3.3%)。
  • 降低临床恶化率的OR值:波生坦+他达拉非(0.08)、波生坦(0.20)、波生坦+西地那非(0.21)、安立生坦+他达拉非(0.27)、西地那非(0.33)、他达拉非(0.44)。

临床怎么用

  • 对于肺动脉高压患者,可考虑内皮素受体拮抗剂与磷酸二酯酶5抑制剂联合治疗以短期改善运动功能。
  • 联合治疗安全性良好,与单药治疗无显著差异。
  • 治疗方案应基于患者个体化情况和需求选择。

局限性

  • 研究仅纳入截至2021年2月12日的文献,未涵盖后续新证据。
  • 原文未报告纳入研究的偏倚风险评估细节。
  • 原文未报告异质性或一致性检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To examine the efficacy and safety of endothelin receptor antagonists (ERA) combined with phosphodiesterase 5 inhibitors (PDE5i) in the treatment of pulmonary artery hypertension (PAH). Methods: Computer-based retrieval was performed on PubMed, Cochrane Library, CNKI, Wanfang, and VIP database (up to February 12th, 2021). Randomized controlled trials about endothelin receptor antagonists (ERAs) or PDE5i in patients with PAH were collected. The change of 6-minute walking distance (6MWD) in 12-16 weeks was used as primary outcome index. Case fatality rate, worsening clinical events, WHO functional class (FC) improvement, adverse events (AEs), serious adverse events (SAE) were the key secondary outcomes indicators. STATA 16.0 software was used for network meta-analysis, and the pooled estimates of odds ratios (ORs) or weighted mean differences (WMDs) and 95% confidence intervals (CIs) of the results were shown. To help explain ORs and WMDs, we used the surface under the cumulative ranking curve (SUCRA) to calculate the probability of each intervention. Results: We included 29 trials with 5 949 participants. In network meta-analysis, Bosentan combined with Sildenafil (WMD=53.93, 95%CI=6.19-101.66) had shown the greatest improvement in 6MWD compared with placebo, followed by Bosentan combined with Tadalafil (WMD=50.84, 95%CI=7.05-94.62), Ambrisentan combined with Tadalafil (WMD=46.67, 95%CI=15.88-77.45), Bosentan (WMD=29.44, 95%CI=5.86-53.02), Ambrisentan (WMD=23.90, 95%CI=0.31-47.48) and Macitentan (WMD=21.57, 95%CI=2.45-40.69). According to SUCRA, the effects of different intervention measures on improving 6MWD in patients with arterial pulmonary hypertension were as follows: Bosentan+Sildenafil (82.9%)>Bosentan+Tadalafil (78.4%)>Ambrisentan+Tadalafil (77.1%)>Bosentan (49.2%)>Sildenafil (48.5%)>Ambrisentan (40.3%)>Macitentan (37.3%)>Tadalafil (33.0%)>Placebo (3.3%). For the WHO functional class, Sildenafil (OR=2.90, 95%CI=1.04-8.08) was optimal compared with placebo, followed by Bosentan (OR=2.15, 95%CI=1.15-4.04), and there was no significant difference in the rest. For clinical worsening, Bosentan combined with Tadalafil (OR=0.08, 95%CI=0.01-0.49) performed best compared with placebo, followed by Bosentan (OR=0.20, 95%CI=0.11-0.38), Bosentan combined with Sildenafil (OR=0.21, 95%CI=0.09-0.46), Ambrisentan combined with Tadalafil (OR=0.27, 95%CI=0.15-0.50), Sildenafil (OR=0.33, 95%CI=0.17-0.66) and Tadalafil (OR=0.44, 95%CI=0.21-0.90). There was no statistical difference between all interventions and placebo in terms of the incidence of adverse events and serious adverse events. For case fatality rate, Ambrisentan (OR=0.28, 95%CI=0.11-0.74) was statistically superior to placebo and there was no statistics difference in the rest. Conclusions: The combination therapy of ERAs and PDE5i performed well in the short-term improvement of motor function. Furthermore, there was no significant difference with monotherapy in terms of safety. However, it is worth emphasizing that the choice of treatment should be based on the patient's individualized situation and the patient's requirements. 目的: 通过网状Meta分析确定内皮素受体拮抗剂联合5型磷酸二酯酶抑制剂治疗动脉性肺动脉高压(PAH)的有效性和安全性。 方法: 使用标准检索式[(“Pulmonary Arterial Hypertension”OR“PAH”)AND(“Bosentan”OR“Ambrisentan”OR“Macitentan”OR“Sildenafil”OR“Tadalafil”)]检索PubMed和Cochrane Library数据库;使用检索词“肺动脉高压”“波生坦”“安立生坦”“马西腾坦”“西地那非”“他达拉非”检索中国知网(CNKI)、万方数据和维普等中文数据库。检索时间截至2021年2月12日。阅读所有文献筛选纳入比较3种内皮素受体拮抗剂和2种5型磷酸二酯酶抑制剂以及联合治疗方案治疗动脉性肺动脉高压的随机对照临床试验(RCT)。以随访12~16周6 min步行距离作为主要结果指标,病死率、临床恶化率、WHO心功能提升、不良事件(AE)和严重不良事件(SAE)作为关键的次要结果指标。使用STATA 16.0软件进行网状Meta分析,合并估计结果的优势比(OR)或加权平均差(WMD)和95%置信区间(CI)。使用累积排名曲线下面积(SUCRA)来计算各干预项的概率,帮助解释OR或WMD。 结果: 共纳入29篇文献,包含5 949例PAH患者。网状Meta分析结果显示,在改善6 min步行距离方面,与安慰剂比较,波生坦+西地那非提升最大(WMD=53.93,95%CI:6.19~101.66),其次为波生坦+他达拉非(WMD=50.84,95%CI:7.05~94.62),安立生坦+他达拉非(WMD=46.67,95%CI:15.88~77.45),波生坦(WMD=29.44,95%CI:5.86~53.02),安立生坦(WMD=23.90,95%CI:0.31~47.48),马西腾坦(WMD=21.57,95%CI:2.45~40.69)。不同干预措施对提高动脉性肺动脉高压患者6 min步行距离的效果,根据SUCRA排序依次为:波生坦+西地那非(82.9%)>波生坦+他达拉非(78.4%)>安立生坦+他达拉非(77.1%)>波生坦(49.2%)>西地那非(48.5%)>安立生坦(40.3%)>马西腾坦(37.3%)>他达拉非(33.0%)>安慰剂(3.3%)。在提高WHO心功能分级方面,与安慰剂相比,西地那非最优(OR=2.90,95%CI:1.04~8.08),其次为波生坦(OR=2.15,95%CI:1.15-4.04),其余差异均无统计学意义。在降低临床恶化率方面,相较于安慰剂,波生坦+他达拉非最优(OR=0.08,95%CI:0.01~0.49),其次依次为波生坦(OR=0.20,95%CI:0.11~0.38),波生坦+西地那非(OR=0.21,95%CI:0.09~0.46),安立生坦+他达拉非(OR=0.27,95%CI:0.15~0.50),西地那非(OR=0.33,95%CI:0.17~0.66),他达拉非(OR=0.44,95%CI:0.21~0.90)。在不良事件发生率与严重不良事件发生率方面,所有干预措施与安慰剂相比差异均无统计学意义。在病死率方面,安立生坦(OR=0.28,95%CI:0.11~0.74)在统计学上优于安慰剂,其余差异均无统计学意义。 结论: 内皮素受体拮抗剂与5型磷酸二酯酶抑制剂联合治疗方案在短期改善运动功能方面均表现较好。并且在安全性方面,与单药治疗并无明显差异。然而,未来在选择治疗方案时,应该根据患者的个体化情况以及患者的需求进行选择。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Fu WH, Chen PL, Xia JL, et al. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis]. Zhonghua Jie He He Hu Xi Za Zhi. 2022. PMID: 35135085. doi:10.3760/cma.j.cn112147-20210707-00473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。